JP2013536855A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013536855A5 JP2013536855A5 JP2013527250A JP2013527250A JP2013536855A5 JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5 JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013527250 A JP2013527250 A JP 2013527250A JP 2013536855 A5 JP2013536855 A5 JP 2013536855A5
- Authority
- JP
- Japan
- Prior art keywords
- rarγ
- use according
- agonist
- muscle tissue
- myopathy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100033912 Retinoic acid receptor gamma Human genes 0.000 claims 18
- 108091008760 retinoic acid receptors γ Proteins 0.000 claims 18
- 239000000556 agonist Substances 0.000 claims 14
- 210000003205 muscle Anatomy 0.000 claims 11
- 208000021642 Muscular disease Diseases 0.000 claims 5
- 201000009623 Myopathy Diseases 0.000 claims 5
- 206010028289 Muscle atrophy Diseases 0.000 claims 4
- 201000000585 muscular atrophy Diseases 0.000 claims 4
- AANFHDFOMFRLLR-UHFFFAOYSA-N 3-fluoro-4-[[2-hydroxy-2-(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)acetyl]amino]benzoic acid Chemical compound C=1C=C2C(C)(C)CCC(C)(C)C2=CC=1C(O)C(=O)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-UHFFFAOYSA-N 0.000 claims 2
- VCQGNUWOMLYNNG-UHFFFAOYSA-N 4-[7-(1-adamantyl)-6-hydroxynaphthalen-2-yl]benzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1C1=CC=C(C=C(O)C(=C2)C34CC5CC(CC(C5)C3)C4)C2=C1 VCQGNUWOMLYNNG-UHFFFAOYSA-N 0.000 claims 2
- 239000005711 Benzoic acid Substances 0.000 claims 2
- LDGIHZJOIQSHPB-UHFFFAOYSA-N CD437 Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1O LDGIHZJOIQSHPB-UHFFFAOYSA-N 0.000 claims 2
- 201000002481 Myositis Diseases 0.000 claims 2
- 102100023606 Retinoic acid receptor alpha Human genes 0.000 claims 2
- LZCDAPDGXCYOEH-UHFFFAOYSA-N adapalene Chemical group C1=C(C(O)=O)C=CC2=CC(C3=CC=C(C(=C3)C34CC5CC(CC(C5)C3)C4)OC)=CC=C21 LZCDAPDGXCYOEH-UHFFFAOYSA-N 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 230000020763 muscle atrophy Effects 0.000 claims 2
- AANFHDFOMFRLLR-LJQANCHMSA-N r-3-fluoro-4-[2-hydroxy-2-(5,5,8,8-tetramethyl-5,6,7,8,-tetrahydro-naphtalen-2-yl)-acetylamino]-benzoic acid Chemical compound O=C([C@H](O)C=1C=C2C(C)(C)CCC(C2=CC=1)(C)C)NC1=CC=C(C(O)=O)C=C1F AANFHDFOMFRLLR-LJQANCHMSA-N 0.000 claims 2
- 108091008726 retinoic acid receptors α Proteins 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 230000000451 tissue damage Effects 0.000 claims 2
- 231100000827 tissue damage Toxicity 0.000 claims 2
- VUXBMFIYPGMZTI-UHFFFAOYSA-N 6-[3-(1-adamantyl)-4-prop-2-ynoxyphenyl]naphthalene-2-carboxylic acid Chemical compound C1C(C2)CC(C3)CC2CC13C1=CC(C2=CC3=CC=C(C=C3C=C2)C(=O)O)=CC=C1OCC#C VUXBMFIYPGMZTI-UHFFFAOYSA-N 0.000 claims 1
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims 1
- YTFHCXIPDIHOIA-DHZHZOJOSA-N Palovarotene Chemical compound C1=CC=NN1CC=1C=C2C(C)(C)CCC(C)(C)C2=CC=1\C=C\C1=CC=C(C(O)=O)C=C1 YTFHCXIPDIHOIA-DHZHZOJOSA-N 0.000 claims 1
- 230000032683 aging Effects 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 230000017531 blood circulation Effects 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 claims 1
- 230000001172 regenerating effect Effects 0.000 claims 1
- 150000004492 retinoid derivatives Chemical class 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 230000002459 sustained effect Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- QERYCTSHXKAMIS-UHFFFAOYSA-N thiophene-2-carboxylic acid Chemical compound OC(=O)C1=CC=CS1 QERYCTSHXKAMIS-UHFFFAOYSA-N 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37899610P | 2010-09-01 | 2010-09-01 | |
| US61/378,996 | 2010-09-01 | ||
| PCT/US2011/049905 WO2012030919A2 (en) | 2010-09-01 | 2011-08-31 | Composition and method for muscle repair and regeneration |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013536855A JP2013536855A (ja) | 2013-09-26 |
| JP2013536855A5 true JP2013536855A5 (https=) | 2014-10-16 |
| JP5986570B2 JP5986570B2 (ja) | 2016-09-06 |
Family
ID=45773490
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013527250A Active JP5986570B2 (ja) | 2010-09-01 | 2011-08-31 | 筋修復および再生のための組成物および方法 |
Country Status (20)
| Country | Link |
|---|---|
| US (6) | US9789074B2 (https=) |
| EP (3) | EP4066826B1 (https=) |
| JP (1) | JP5986570B2 (https=) |
| CN (2) | CN103200937B (https=) |
| AU (1) | AU2011296080B2 (https=) |
| BR (1) | BR112013004685B1 (https=) |
| CA (1) | CA2809374C (https=) |
| CL (1) | CL2013000580A1 (https=) |
| CO (1) | CO6680694A2 (https=) |
| DK (2) | DK2613776T3 (https=) |
| EA (1) | EA026251B1 (https=) |
| ES (3) | ES2912593T3 (https=) |
| HU (2) | HUE051664T2 (https=) |
| IL (1) | IL224973B (https=) |
| MX (2) | MX361414B (https=) |
| NZ (1) | NZ607547A (https=) |
| PL (2) | PL3721880T3 (https=) |
| PT (1) | PT2613776T (https=) |
| WO (1) | WO2012030919A2 (https=) |
| ZA (1) | ZA201301536B (https=) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4066826B1 (en) | 2010-09-01 | 2024-03-06 | Thomas Jefferson University | Retinoic acid receptor gamma agonists for muscle repair and regeneration |
| US9782417B2 (en) | 2011-06-16 | 2017-10-10 | Presidents And Fellows Of Harvard College | Methods of increasing satellite cell proliferation with kinase inhibitors |
| WO2017136480A1 (en) * | 2016-02-01 | 2017-08-10 | President And Fellows Of Harvard College | Small molecules for mouse satellite cell proliferation |
| US11963964B2 (en) | 2011-06-16 | 2024-04-23 | President And Fellows Of Harvard College | Small molecules for mouse satellite cell proliferation |
| US11026952B2 (en) | 2011-06-16 | 2021-06-08 | President And Fellows Of Harvard College | Small molecules for mouse satellite cell proliferation |
| CA2890424C (en) | 2012-11-08 | 2020-11-17 | Yamaguchi University | Therapeutic agent for keratoconjunctive disorders |
| GB2524707B (en) * | 2013-01-09 | 2020-04-22 | Int Stem Cell Corporation | Small molecules that promote skin regeneration |
| RS58045B1 (sr) * | 2013-05-22 | 2019-02-28 | Univ Yamaguchi | Inhibitor za retinohoroidalne poremećaje |
| US20170114019A1 (en) | 2014-06-04 | 2017-04-27 | Haro Pharmaceutical Inc. | 18-20 member bi-polycyclic compounds |
| US9784665B1 (en) * | 2014-12-29 | 2017-10-10 | Flagship Biosciences, Inc. | Methods for quantitative assessment of muscle fibers in muscular dystrophy |
| BR112017023748A2 (pt) | 2015-05-06 | 2018-07-31 | University Of Southern California | métodos para tratar hipertensão; reduzir níveis de colesterol elevados e/ou níveis de ldl elevados; reduzir níveis de triglicerídeo elevados e/ou níveis de crp elevados; tratar um indivíduo com níveis de insulina ou glicose elevados; tratar obesidade abdominal; tratar um indivíduo com níveis de igf-1 elevados; tratar ou prevenir inflamação; aumentar regeneração; e reduzir fígado gorduroso |
| EP3091084A1 (en) | 2015-05-08 | 2016-11-09 | Université Catholique De Louvain | Methods for assessing the purity of a mesenchymal stem cells preparation |
| SG11201810658PA (en) | 2016-06-08 | 2018-12-28 | Clementia Pharmaceuticals Inc | Methods for treating heterotopic ossification |
| MX379489B (es) | 2016-11-16 | 2025-03-11 | Clementia Pharmaceuticals Inc | Metodos para tratar la osteocondromatosis multiple (mo). |
| CA3019069A1 (en) * | 2018-04-02 | 2019-10-02 | Hubit Genomix, Inc. | Prophylactic and/or therapeutic drug for diabetic nephropathy |
| US11135236B2 (en) * | 2018-04-10 | 2021-10-05 | Northwestern University | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity |
| GB201907647D0 (en) * | 2019-05-30 | 2019-07-17 | King S College London | Therapeutic methods |
| FR3112684B1 (fr) * | 2020-07-24 | 2022-08-12 | Univ Grenoble Alpes | Composés pour le traitement de l’hémophilie |
| CN116891497B (zh) * | 2022-04-02 | 2025-12-16 | 上海旭成医药科技有限公司 | 视黄酸受体激动剂、其制备方法、中间体、药物组合物和应用 |
| US20250367183A1 (en) * | 2022-06-16 | 2025-12-04 | Institute Of Zoology, Chinese Academy Of Sciences | Substance for promoting regeneration and repair of organs of mammals and use thereof |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3270960A (en) | 1964-09-11 | 1966-09-06 | Sperry Rand Corp | Fluid sensor |
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| EP0139676B1 (en) | 1983-02-04 | 1992-11-25 | Cytoclonal Pharmaceutics Inc. | Production and characterization of hybridoma antibodies directed specifically against common determinant(s) present among closely related, but distinct proteins |
| GB2148299B (en) | 1983-09-01 | 1988-01-06 | Hybritech Inc | Antibody compositions of therapeutic agents having an extended serum half-life |
| JPS6253981A (ja) | 1985-09-02 | 1987-03-09 | Koichi Shiyudo | 新規安息香酸誘導体 |
| AU618590B2 (en) | 1988-04-11 | 1992-01-02 | Allergan, Inc. | Tetralin esters of phenols or benzoic acids having retinoid like activity |
| CA2129773C (en) | 1993-09-02 | 2007-05-01 | Michael Klaus | Aromatic carboxylic acid derivatives |
| US5408002A (en) | 1993-09-09 | 1995-04-18 | Minnesota Mining And Manufacturing Company | Azlactone-functional polymer blends, articles produced therefrom and methods for preparing both |
| US5498795A (en) | 1994-12-29 | 1996-03-12 | Allergan, Inc. | Acetylenes disubstituted with hydroxyaryl and aryl or heteroaryl groups having retinoid-like biological activity |
| US5843780A (en) | 1995-01-20 | 1998-12-01 | Wisconsin Alumni Research Foundation | Primate embryonic stem cells |
| US5807900A (en) | 1995-03-31 | 1998-09-15 | Hoffmann-La Roche, Inc. | Method for identifying compounds having increased activity for the repair of skin photodamage |
| US5624957A (en) | 1995-06-06 | 1997-04-29 | Bristol-Myers Squibb Company | Rary-specific retinobenzoic acid derivatives |
| FR2739557B1 (fr) * | 1995-10-09 | 1997-11-14 | Cird Galderma | Utilisation d'un ligand agoniste specifique rar-gamma |
| FR2739777B1 (fr) * | 1995-10-11 | 1997-11-14 | Cird Galderma | Ligand antagoniste rar-gamma ou agoniste rar-alpha en tant qu'inhibiteur d'apoptose |
| US5726191A (en) | 1995-11-16 | 1998-03-10 | Hoffmann-La Roche Inc. | Aromatic carboxylic acid esters |
| US5994619A (en) | 1996-04-01 | 1999-11-30 | University Of Massachusetts, A Public Institution Of Higher Education Of The Commonwealth Of Massachusetts, As Represented By Its Amherst Campus | Production of chimeric bovine or porcine animals using cultured inner cell mass cells |
| FR2747041B1 (fr) | 1996-04-05 | 1998-05-22 | Cird Galderma | Utilisation de derives benzonaphtaleniques pour la fabrication de medicaments destines au traitement des neuropathies |
| US5945577A (en) | 1997-01-10 | 1999-08-31 | University Of Massachusetts As Represented By Its Amherst Campus | Cloning using donor nuclei from proliferating somatic cells |
| US5919970A (en) | 1997-04-24 | 1999-07-06 | Allergan Sales, Inc. | Substituted diaryl or diheteroaryl methanes, ethers and amines having retinoid agonist, antagonist or inverse agonist type biological activity |
| AU7481098A (en) * | 1997-05-13 | 1998-12-08 | Case Western Reserve University | Osteoarthritis cartilage regeneration using human mesenchymal stem ce lls |
| US7514074B2 (en) * | 1997-07-14 | 2009-04-07 | Osiris Therapeutics, Inc. | Cardiac muscle regeneration using mesenchymal stem cells |
| PT1082410E (pt) | 1998-05-29 | 2007-11-09 | Osiris Therapeutics Inc | Células estaminais mesenquimatosas humanas cd45+ e/ou fibroblastos+ |
| CA2344919A1 (en) | 1998-09-24 | 2000-03-30 | Bristol-Myers Squibb Company | Active enantiomer of rar.gamma.-specific agonist |
| JO2178B1 (en) | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of emphysema using rar selective retinoid antagonists |
| US20030114482A1 (en) | 1999-12-15 | 2003-06-19 | Maurizio Pacifici | Use of retinoid receptor antagonists or agonists in the treatment of cartilage and bone pathologies |
| US6313168B1 (en) | 1999-12-15 | 2001-11-06 | Allergan Sales, Inc. | Use of retinoid receptor antagonists in the treatment of cartilage and bone pathologies |
| US20030125252A1 (en) | 2000-03-14 | 2003-07-03 | Underhill T. Michael | Compositions and methods for affecting osteogenesis |
| ATE328067T1 (de) | 2000-04-28 | 2006-06-15 | Childrens Medical Center | Isolierung von mesenchymalen stammzellen und deren verwendung |
| DE60136477D1 (de) | 2000-10-02 | 2008-12-18 | Hoffmann La Roche | Retinoide zur behandlung von emphysem |
| US7087726B2 (en) | 2001-02-22 | 2006-08-08 | Genentech, Inc. | Anti-interferon-α antibodies |
| MXPA04002590A (es) | 2001-09-18 | 2004-06-18 | Hoffmann La Roche | Agonistas retinoides i de alquil urea. |
| CN1301968C (zh) | 2001-09-18 | 2007-02-28 | 霍夫曼-拉罗奇有限公司 | 取代的脲的类维生素a激动剂ⅱ |
| AUPR892501A0 (en) * | 2001-11-16 | 2001-12-13 | Peter Maccallum Cancer Institute, The | Method of enhancing self renewal of stem cells and uses thereof |
| US7592174B2 (en) | 2002-05-31 | 2009-09-22 | The Board Of Trustees Of The Leland Stanford Junior University | Isolation of mesenchymal stem cells |
| AU2003273556A1 (en) * | 2002-06-04 | 2003-12-19 | Galderma Research & Development, S.N.C. | Ligands that are inhibitors of the rar receptors |
| AU2003228099A1 (en) * | 2002-07-03 | 2004-01-23 | Centro Cardiologico Monzino S.P.A.-Irccs | Use of hmgb1 in the treatment of tissue damage and/or to promote tissue repair |
| EP1551955A4 (en) | 2002-07-16 | 2006-11-29 | Yissum Res Dev Co | METHOD FOR IMPLANTING MESENCHYMAL STEM CELLS FOR TISSUE PAIRING AND FORMATION |
| US20050101581A1 (en) | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
| NZ547157A (en) | 2003-12-10 | 2009-07-31 | Medarex Inc | Interferon Alpha Antibodies and their uses |
| JP2005206544A (ja) | 2004-01-23 | 2005-08-04 | Yasuyoshi Uchida | 筋肉再生剤 |
| AU2005240078A1 (en) * | 2004-04-30 | 2005-11-17 | Allergan, Inc. | Retinoid-containing sustained release intraocular drug delivery systems and related methods of manufacturing |
| WO2005115304A2 (en) | 2004-05-24 | 2005-12-08 | Ab Science | Use of c-kit inhibitors for treating fibrodysplasia |
| US7345931B2 (en) | 2005-08-01 | 2008-03-18 | Infineon Technologies Ag | Maintaining internal voltages of an integrated circuit in response to a clocked standby mode |
| FR2894959B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteur rar-gamma |
| FR2894960B1 (fr) | 2005-12-15 | 2008-02-29 | Galderma Res & Dev | Derives biphenyliques agonistes selectifs du recepteurs rar-gamma |
| JP2009527465A (ja) | 2006-01-26 | 2009-07-30 | コンビナトアールエックス インコーポレーティッド | 筋骨格障害およびそれに関連する症状の処置のための方法、組成物およびキット |
| JP5113038B2 (ja) * | 2006-03-23 | 2013-01-09 | テムリック株式会社 | 癌治療用キットおよび癌治療用医薬組成物 |
| AU2007233868A1 (en) | 2006-03-31 | 2007-10-11 | F. Hoffmann-La Roche Ag | Process for preparing retinoid compounds |
| DK2026778T3 (en) | 2006-05-16 | 2019-01-07 | Io Therapeutics Llc | RAR ANTAGONIST OR INVERSE AGONIST FOR USE IN THE TREATMENT OF CHEMOTHERAPY AND / OR RADIATION THERAPY SIDE EFFECTS |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| JP5638961B2 (ja) | 2008-03-13 | 2014-12-10 | ザ ジェネラル ホスピタル コーポレイション | Ｂｍｐシグナル伝達経路のインヒビター |
| EP2379174A4 (en) | 2008-12-18 | 2012-11-14 | Astrazeneca Ab | PHARMACEUTICAL PRODUCT USING A P38 KINASE INHIBITOR AND A SECOND ACTIVE SUBSTANCE |
| WO2010088735A1 (en) * | 2009-02-05 | 2010-08-12 | Regenertech Pty Ltd | Method of producing progenitor cells from differentiated cells |
| WO2011011513A1 (en) | 2009-07-21 | 2011-01-27 | University Of Washington Through Its Center For Commercialization | Inhibition of pathological bone formation |
| UA50725U (ru) * | 2009-12-01 | 2010-06-25 | Институт Нейрохирургии Им. Акад. А.П. Ромоданова Амн Украины | Способ лечения больных с прогрессирующей мышечной дистрофией трансплантацией миобластов эмбриона человека |
| EP4066826B1 (en) | 2010-09-01 | 2024-03-06 | Thomas Jefferson University | Retinoic acid receptor gamma agonists for muscle repair and regeneration |
| WO2012125724A1 (en) | 2011-03-14 | 2012-09-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of proliferative disorders |
| WO2012129562A2 (en) | 2011-03-24 | 2012-09-27 | The Scripps Research Institute | Compounds and methods for inducing chondrogenesis |
| US20140220154A1 (en) | 2011-07-01 | 2014-08-07 | The United States Of America, As Represented By The Secretary, Dept. Of Health And Human Service | Method of treating pathologic heterotopic ossification |
| EP2817292B1 (en) | 2012-02-22 | 2019-12-18 | Sanford-Burnham Medical Research Institute | Sulfonamide compounds and uses as tnap inhibitors |
| KR102092988B1 (ko) | 2012-09-28 | 2020-03-25 | 벤더르빌트 유니버시티 | 선택성 bmp 저해제로써 융합된 헤테로 고리 화합물들 |
| WO2014138088A1 (en) | 2013-03-04 | 2014-09-12 | The Brigham And Women's Hospital, Inc. | Bmp inhibitors and methods of use thereof |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| RS58045B1 (sr) | 2013-05-22 | 2019-02-28 | Univ Yamaguchi | Inhibitor za retinohoroidalne poremećaje |
| US20170305883A1 (en) | 2014-10-01 | 2017-10-26 | The Brigham And Women's Hospital, Inc. | Compositions and Methods for Inhibiting BMP |
| US20180311356A1 (en) | 2015-10-19 | 2018-11-01 | The Children's Medical Center Corporation | Method to inhibit endothelial-to-mesenchymal transition |
| JP6589119B2 (ja) | 2015-12-24 | 2019-10-16 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガンＴｈｅ Ｒｅｇｅｎｔｓ Ｏｆ Ｔｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｍｉｃｈｉｇａｎ | 異所性骨化を治療する方法 |
| SG11201810658PA (en) | 2016-06-08 | 2018-12-28 | Clementia Pharmaceuticals Inc | Methods for treating heterotopic ossification |
| JP6630255B2 (ja) | 2016-09-30 | 2020-01-15 | 株式会社沖データ | 画像形成装置及び通信システム |
-
2011
- 2011-08-31 EP EP22154427.3A patent/EP4066826B1/en active Active
- 2011-08-31 CN CN201180052926.XA patent/CN103200937B/zh active Active
- 2011-08-31 MX MX2013002275A patent/MX361414B/es active IP Right Grant
- 2011-08-31 ES ES20171639T patent/ES2912593T3/es active Active
- 2011-08-31 PL PL20171639T patent/PL3721880T3/pl unknown
- 2011-08-31 HU HUE11822537A patent/HUE051664T2/hu unknown
- 2011-08-31 ES ES22154427T patent/ES2975123T3/es active Active
- 2011-08-31 AU AU2011296080A patent/AU2011296080B2/en active Active
- 2011-08-31 PL PL11822537T patent/PL2613776T3/pl unknown
- 2011-08-31 EP EP20171639.6A patent/EP3721880B1/en active Active
- 2011-08-31 PT PT118225374T patent/PT2613776T/pt unknown
- 2011-08-31 JP JP2013527250A patent/JP5986570B2/ja active Active
- 2011-08-31 NZ NZ607547A patent/NZ607547A/en unknown
- 2011-08-31 EA EA201370051A patent/EA026251B1/ru unknown
- 2011-08-31 CN CN202010493245.8A patent/CN111773213B/zh active Active
- 2011-08-31 DK DK11822537.4T patent/DK2613776T3/da active
- 2011-08-31 DK DK20171639.6T patent/DK3721880T3/da active
- 2011-08-31 US US13/819,914 patent/US9789074B2/en active Active
- 2011-08-31 CA CA2809374A patent/CA2809374C/en active Active
- 2011-08-31 HU HUE20171639A patent/HUE059024T2/hu unknown
- 2011-08-31 ES ES11822537T patent/ES2823234T3/es active Active
- 2011-08-31 WO PCT/US2011/049905 patent/WO2012030919A2/en not_active Ceased
- 2011-08-31 BR BR112013004685-6A patent/BR112013004685B1/pt active IP Right Grant
- 2011-08-31 EP EP11822537.4A patent/EP2613776B1/en active Active
-
2013
- 2013-02-26 MX MX2018015032A patent/MX2018015032A/es unknown
- 2013-02-28 IL IL224973A patent/IL224973B/en active IP Right Grant
- 2013-02-28 CL CL2013000580A patent/CL2013000580A1/es unknown
- 2013-02-28 ZA ZA2013/01536A patent/ZA201301536B/en unknown
- 2013-03-05 CO CO13044010A patent/CO6680694A2/es not_active Application Discontinuation
-
2014
- 2014-06-18 US US14/308,570 patent/US9314439B2/en active Active
-
2017
- 2017-08-10 US US15/674,357 patent/US10292954B2/en active Active
-
2019
- 2019-04-09 US US16/379,178 patent/US11433039B2/en active Active
-
2022
- 2022-08-04 US US17/881,207 patent/US12023312B2/en active Active
-
2024
- 2024-05-06 US US18/655,854 patent/US20250108022A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013536855A5 (https=) | ||
| JP2005522476A5 (https=) | ||
| JP2012502957A5 (https=) | ||
| Orfanos et al. | Oral retinoids in the treatment of seborrhoea and acne | |
| JP5172911B2 (ja) | 癒着の予防及び／又は治療のための医薬 | |
| PT637297E (pt) | Compostos com selectividade para os receptores de retinoide x | |
| JP2007504212A5 (https=) | ||
| RU2017129434A (ru) | Амидные производные n-карбамид-замещенных аминокислот как модуляторы формилпептидного рецептора-1 (fprl-1) | |
| JP2014062126A5 (https=) | ||
| JP2004534825A5 (https=) | ||
| SI1507558T1 (sl) | Farmacevtski sestavek, ki obsega reninski inhibitor, blokator kalcijevega kanala in diuretik | |
| JP2010523623A5 (https=) | ||
| AU2010320911B2 (en) | Combination of alpha- 2 adrenergic receptor agonist and non-steroidal anti - inflammatory agent for treating or preventing an inflammatory skin disorder | |
| JP2006503809A5 (https=) | ||
| Hoxha | Duchenne muscular dystrophy: Focus on arachidonic acid metabolites | |
| Yoshinaga et al. | Imaging myocardial metabolism | |
| RU2020117569A (ru) | Препарат для местного применения для лечения трихофитического онихомикоза | |
| JP2017528521A5 (https=) | ||
| JP2010522711A5 (https=) | ||
| JP2008537547A5 (https=) | ||
| JP2009504774A5 (https=) | ||
| JPWO2024090521A5 (https=) | ||
| JP2013516475A5 (https=) | ||
| JP2005517649A5 (https=) | ||
| RU2009127747A (ru) | Применение непафенака или его производных для лечения дерматологических расстройств, связанных с нарушением кератинизации, которое может иметь иммуно-аллергическую воспалительную составляющую |